Related Experiment Videos
Abstract:
Amikacin, a semisynthetic analog of kanamycin, is very active against most gram-negative bacteria including gentamicin- and tobramycin-resistant strains. The effectiveness of amikacin in the treatment of serious gram-negative bacillary infections is well documented. Due to its resistance to inactivating enzymes, it is the aminoglycoside of choice for the treatment of known or suspected serious gram-negative infections caused by organisms resistant to gentamicin or tobramycin. Amikacin should be part of an empiric antibiotic regimen for the therapy of suspected sepsis in febrile, leukopenic immunocompromised hosts since it exhibits enhanced activity against the organisms most frequently encountered in this patient population. High response rates have been reported with the use of amikacin combined with beta-lactam antibiotics in immunocompromised or granulocytopenic patients. It exhibits impressive in vitro synergy against aminoglycoside-sensitive and -resistant organisms when used in combination with the new acylureidopenicillins and third-generation cephalosporins. Amikacin has the advantage of being the aminoglycoside least inactivated by the semisynthetic penicillins. Amikacin achieves high and predictable serum concentrations and has a favorable therapeutic index. Its potential for nephrotoxicity and ototoxicity is not significantly different than that encountered with gentamicin or tobramycin. Amikacin appears to be the preferred aminoglycoside for use at the present time because of its activity against gentamicin- and tobramycin-resistant organisms, its low resistance potential, its relative low degree of inactivation by the semisynthetic penicillins, and its superior pharmacokinetic profile.
Insights
Amikacin is a preferred aminoglycoside antibiotic effective against resistant gram-negative bacteria. It shows synergy with other antibiotics and has a favorable pharmacokinetic profile, making it ideal for serious infections.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Amikacin, a kanamycin analog, demonstrates broad-spectrum activity against Gram-negative bacteria.
- It is effective against strains resistant to gentamicin and tobramycin.
- Its resistance to inactivating enzymes makes it a key choice for serious Gram-negative infections.
Purpose of the Study:
- To evaluate the efficacy and suitability of amikacin as a preferred aminoglycoside antibiotic.
- To highlight its role in treating infections caused by resistant organisms.
- To discuss its use in immunocompromised patients and in combination therapies.
Main Methods:
- Review of existing clinical data and in vitro studies on amikacin.
- Analysis of amikacin's activity against resistant bacterial strains.
- Assessment of its pharmacokinetic profile and therapeutic index.
Main Results:
- Amikacin exhibits high activity against Gram-negative bacteria, including resistant strains.
- It shows synergistic effects when combined with beta-lactam antibiotics and third-generation cephalosporins.
- Amikacin has a favorable therapeutic index with predictable serum concentrations and manageable toxicity.
Conclusions:
- Amikacin is the preferred aminoglycoside due to its activity against resistant organisms, low resistance potential, and favorable pharmacokinetics.
- It is a valuable component of empiric antibiotic regimens for suspected sepsis in immunocompromised hosts.
- Its combination with other antibiotics enhances treatment outcomes in severe infections.